Image Place holder

Laura Kruper, MD

 
Specialty: Surgery
Program: Breast Oncology

Overview

Cancer Focus: Breast Cancer

Dr. Laura Kruper is a Senior Member and Breast Surgeron in the Department of Breast Oncology at Moffitt Cancer Center. Dr. Laura Kruper received her MD and Master of Science in Clinical Epidemiology degree from the University of Pennsylvania School of Medicine. Dr. Kruper completed a General Surgery Residency at the Hospital of the University of Pennsylvania, where she also served as Chief Resident. She completed a Breast Oncology Fellowship at the John Wayne Cancer Institution, Santa Monica, California. Dr, Kruper joins us from City of Hope Cancer Center, where she served as the Chief of the Division of Breast Surgery for the entire City of Hope system, and the Program Director of the Breast Surgery Training Program. Dr. Kruper’s clinical focus is to treat the full range of breast conditions, from benign breast masses to advanced breast cancers. Dr. Kruper’s research interests include reducing health care disparities in the treatment of breast cancer. She is also focused on de-escalating systemic breast cancer treatment, while bringing new technologies and therapies to breast cancer surgery to minimize toxicities and improve outcomes.


Education & Training

Participating Trials

If you believe you are eligible for one of these trials or studies, please call
813-745-6100 or toll-free 1-800-679-0775.

Publications

  • Jones VC, Chlebowski RT, Pan K, Kruper L, Mortimer J, Nassir R, Nelson RA. African Ancestry and Triple-Negative Breast Cancer in the Women's Health Initiative. Am Surg. 2022 Jul.88(7):1722-1724. Pubmedid: 32909446. Pmcid: PMC8976497.
  • Gonzalez L, Sun C, Loscalzo M, Clark K, Kruper L, Mortimer J, Jones V. A Cross-Sectional Study of Distress Levels in Patients with Newly Diagnosed Breast Cancer: The Impact of Race, Ethnicity, and Language Preference. Ann Surg Oncol. 2022 Feb.29(2):981-988. Pubmedid: 34585296.
  • Egelston CA, Guo W, Tan J, Avalos C, Simons DL, Lim MH, Huang YJ, Nelson MS, Chowdhury A, Schmolze DB, Yim JH, Kruper L, Melstrom L, Margolin K, Mortimer JE, Yuan Y, Waisman JR, Lee PP. Tumor-infiltrating exhausted CD8+ T cells dictate reduced survival in premenopausal estrogen receptor-positive breast cancer. JCI Insight. 2022 Feb.7(3). Pubmedid: 35132960. Pmcid: PMC8855819.
  • Yuan Y, Lee JS, Yost SE, Li SM, Frankel PH, Ruel C, Schmolze D, Robinson K, Tang A, Martinez N, Stewart D, Waisman J, Kruper L, Jones V, Menicucci A, Uygun S, Yoder E, van der Baan B, Yim JH, Yeon C, Somlo G, Mortimer J. Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer. Oncologist. 2021 Mar.26(3):e382-e393. Pubmedid: 33098195. Pmcid: PMC7930424.
  • Bosserman LD, Cianfrocca M, Yuh B, Yeon C, Chen H, Sentovich S, Polverini A, Zachariah F, Deaville D, Lee AB, Sedrak MS, King E, Gray S, Morse D, Glaser S, Bhatt G, Adeimy C, Tan T, Chao J, Nam A, Paz IB, Kruper L, Rao P, Sokolov K, Kulkarni P, Salgia R, Yamzon J, Johnson D. Integrating Academic and Community Cancer Care and Research through Multidisciplinary Oncology Pathways for Value-Based Care: A Review and the City of Hope Experience. J Clin Med. 2021 Jan.10(2). Pubmedid: 33430334. Pmcid: PMC7825796.
  • Mortimer JE, Kruper L, Jung J, Wong L, Cooper J, Stewart D, Chung S, Yu KW, Dadwal S, Yuan Y. Characterization of infections and hypogammaglobulinemia treated with the combination of pertuzumab and trastuzumab. Cancer Chemother Pharmacol. 2020 Mar.85(3):501-507. Pubmedid: 31641845. Pmcid: PMC7036067.
  • Mortimer JE, Kruper L, Cianfrocca M, Lavasani S, Liu S, Tank-Patel N, Sedrak M, Smith W, Stewart D, Waisman J, Yeon C, Wang T, Yuan Y. Use of HER2-Directed Therapy in Metastatic Breast Cancer and How Community Physicians Collaborate to Improve Care. J Clin Med. 2020 Jun.9(6). Pubmedid: 32599960. Pmcid: PMC7355741.
  • Nelson RA, Bostanci Z, Jones V, Mortimer J, Polverini A, Taylor L, Yee L, Yim JH, Kruper L. Insurance Status Predicts Survival in Women with Breast Cancer: Results of Breast and Cervical Cancer Treatment Program in California. Ann Surg Oncol. 2020 Jul.27(7):2177-2187. Pubmedid: 31965375. Pmcid: PMC8838883.
  • Zhang C, Yue C, Herrmann A, Song J, Egelston C, Wang T, Zhang Z, Li W, Lee H, Aftabizadeh M, Li YJ, Lee PP, Forman S, Somlo G, Chu P, Kruper L, Mortimer J, Hoon DSB, Huang W, Priceman S, Yu H. STAT3 Activation-Induced Fatty Acid Oxidation in CD8+ T Effector Cells Is Critical for Obesity-Promoted Breast Tumor Growth. Cell Metab. 2020 Jan.31(1):148-161.e5. Pubmedid: 31761565. Pmcid: PMC6949402.
  • Egelston CA, Avalos C, Tu TY, Rosario A, Wang R, Solomon S, Srinivasan G, Nelson MS, Huang Y, Lim MH, Simons DL, He TF, Yim JH, Kruper L, Mortimer J, Yost S, Guo W, Ruel C, Frankel PH, Yuan Y, Lee PP. Resident memory CD8+ T cells within cancer islands mediate survival in breast cancer patients. JCI Insight. 2019 Oct.4(19). Pubmedid: 31465302. Pmcid: PMC6795408.
  • Crew KD, Anderson GL, Hershman DL, Terry MB, Tehranifar P, Lew DL, Yee M, Brown EA, Kairouz SS, Kuwajerwala N, Bevers T, Doster JE, Zarwan C, Kruper L, Minasian LM, Ford L, Arun B, Neuhouser M, Goodman GE, Brown PH. Randomized Double-Blind Placebo-Controlled Biomarker Modulation Study of Vitamin D Supplementation in Premenopausal Women at High Risk for Breast Cancer (SWOG S0812). Cancer Prev Res (Phila). 2019 Jul.12(7):481-490. Pubmedid: 31138522. Pmcid: PMC6609474.
  • Petrossian K, Kanaya N, Lo C, Hsu PY, Nguyen D, Yang L, Yang L, Warden C, Wu X, Pillai R, Bernal L, Huang CS, Kruper L, Yuan Y, Somlo G, Mortimer J, Chen S. ERα-mediated cell cycle progression is an important requisite for CDK4/6 inhibitor response in HR+ breast cancer. Oncotarget. 2018 Jun.9(45):27736-27751. Pubmedid: 29963233. Pmcid: PMC6021239.
  • Hsu PY, Wu VS, Kanaya N, Petrossian K, Hsu HK, Nguyen D, Schmolze D, Kai M, Liu CY, Lu H, Chu P, Vito CA, Kruper L, Mortimer J, Chen S. Dual mTOR Kinase Inhibitor MLN0128 Sensitizes HR+/HER2+ Breast Cancer Patient-Derived Xenografts to Trastuzumab or Fulvestrant. Clin Cancer Res. 2018 Jan.24(2):395-406. Pubmedid: 29079660. Pmcid: PMC8820221.
  • Dumitra S, Jones V, Rodriguez J, Bitz C, Polamero E, Loscalzo M, Kruper L, Warner SG. Disparities in managing emotions when facing a diagnosis of breast cancer: Results of screening program of couples distress. Surgery. 2018 Jan. Pubmedid: 29370926.
  • Kanaya N, Somlo G, Wu J, Frankel P, Kai M, Liu X, Wu SV, Nguyen D, Chan N, Hsieh MY, Kirschenbaum M, Kruper L, Vito C, Badie B, Yim JH, Yuan Y, Hurria A, Peiguo C, Mortimer J, Chen S. Characterization of patient-derived tumor xenografts (PDXs) as models for estrogen receptor positive (ER+HER2- and ER+HER2+) breast cancers. J Steroid Biochem -. 2017 Jun.170:65-74. Pubmedid: 27154416. Pmcid: PMC5094906.
  • Kauffmann RM, Goldstein L, Marcinkowski E, Somlo G, Yuan Y, Ituarte PH, Kruper L, Taylor L, Vito C. Predictors of Antiestrogen Recommendation in Women With Estrogen Receptor-Positive Ductal Carcinoma In Situ. J Natl Compr Canc Ne. 2016 Sep.14(9):1081-1090. Pubmedid: 27587621. Pmcid: PMC9206878.
  • Polverini AC, Nelson RA, Marcinkowski E, Jones VC, Lai L, Mortimer JE, Taylor L, Vito C, Yim J, Kruper L. Time to Treatment: Measuring Quality Breast Cancer Care. Ann Surg Oncol. 2016 Oct.23(10):3392-3402. Pubmedid: 27503492.
  • Kauffmann R, Bitz C, Clark K, Loscalzo M, Kruper L, Vito C. Addressing psychosocial needs of partners of breast cancer patients: a pilot program using social workers to improve communication and psychosocial support. Support Care Cancer. 2016 Jan.24(1):61-65. Pubmedid: 25917451.
  • Lee M, Reinertsen E, McClure E, Liu S, Kruper L, Tanna N, Brian Boyd J, Granzow JW. Surgeon motivations behind the timing of breast reconstruction in patients requiring postmastectomy radiation therapy. J Plast Reconstr Aesthet Surg. 2015 Nov.68(11):1536-1542. Pubmedid: 26277336. Pmcid: PMC4659387.
  • Bitz C, Clark K, Vito C, Kruper L, Ituarte PH, Loscalzo M. Partners' clinic: an innovative gender strengths-based intervention for breast cancer patients and their partners immediately prior to initiating care with their treating physician. Psychooncology. 2015 Mar.24(3):355-358. Pubmedid: 24924215.
  • Merchant SJ, Goldstein L, Kruper LL. Patterns and Trends in Immediate Postmastectomy Reconstruction in California: Complications and Unscheduled Readmissions. Plast Reconstr Surg. 2015 Jul.136(1):10e-19e. Pubmedid: 26111325.
  • Shinde AM, Zhai J, Yu KW, Frankel P, Yim JH, Luu T, Kruper L, Vito C, Shaw S, Vora NL, Kirschenbaum M, Somlo G. Pathologic complete response rates in triple-negative, HER2-positive, and hormone receptor-positive breast cancers after anthracycline-free neoadjuvant chemotherapy with carboplatin and paclitaxel with or without trastuzumab. Breast. 2015 Feb.24(1):18-23. Pubmedid: 25467313. Pmcid: PMC4596816.
  • Patel SK, Wong AL, Wong FL, Breen EC, Hurria A, Smith M, Kinjo C, Paz IB, Kruper L, Somlo G, Mortimer JE, Palomares MR, Irwin MR, Bhatia S. Inflammatory Biomarkers, Comorbidity, and Neurocognition in Women With Newly Diagnosed Breast Cancer. J Natl Cancer Inst. 2015 Aug.107(8). Pubmedid: 26101331. Pmcid: PMC4609551.
  • Kruper L, Kauffmann RM, Smith DD, Nelson RA. Survival analysis of contralateral prophylactic mastectomy: a question of selection bias. Ann Surg Oncol. 2014 Oct.21(11):3448-3456. Pubmedid: 25047478.
  • Miller M, Ottesen RA, Niland JC, Kruper L, Chen SL, Vito C. Tumor response ratio predicts overall survival in breast cancer patients treated with neoadjuvant chemotherapy. Ann Surg Oncol. 2014 Oct.21(10):3317-3323. Pubmedid: 25059788.
  • Arrington AK, Goldstein L, Kruper L, Vito C, Yim J, Chen SL. Life expectancy after curative-intent treatment of breast cancer: impact on long-term follow-up care. Am Surg. 2014 Jun.80(6):604-609. Pubmedid: 24887800.
  • Mortimer J, Jung J, Yuan Y, Kruper L, Stewart D, Chung S, Yu KW, Mendelsohn M, D'Apuzzo M, Tegtmeier B, Dadwal S. Skin/nail infections with the addition of pertuzumab to trastuzumab-based chemotherapy. Breast Cancer Res Treat. 2014 Dec.148(3):563-570. Pubmedid: 25385180. Pmcid: PMC4243002.
  • Arrington AK, Kruper L, Vito C, Yim J, Kim J, Chen SL. Rural and urban disparities in the evolution of sentinel lymph node utilization in breast cancer. Am J Surg. 2013 Nov.206(5):674-681. Pubmedid: 24035212.
  • Kruper L, Xu XX, Henderson K, Bernstein L, Chen SL. Utilization of mastectomy and reconstruction in the outpatient setting. Ann Surg Oncol. 2013 Mar.20(3):828-835. Pubmedid: 22990647. Pmcid: PMC3819218.
  • Priceman SJ, Kujawski M, Shen S, Cherryholmes GA, Lee H, Zhang C, Kruper L, Mortimer J, Jove R, Riggs AD, Yu H. Regulation of adipose tissue T cell subsets by Stat3 is crucial for diet-induced obesity and insulin resistance. Proc Natl Acad Sci U S A. 2013 Aug.110(32):13079-13084. Pubmedid: 23878227. Pmcid: PMC3740863.
  • Pal SK, Dehaven M, Nelson RA, Onami S, Hsu J, Waliany S, Kruper L, Mortimer J. Impact of modern chemotherapy on the survival of women presenting with de novo metastatic breast cancer. BMC Cancer. 2012 Sep.12:435. Pubmedid: 23020297. Pmcid: PMC3526502.
  • Oxner CR, Vora L, Yim J, Kruper L, Ellenhorn JD. Magnetic resonance imaging-guided breast biopsy in lesions not visualized by mammogram or ultrasound. Am Surg. 2012 Oct.78(10):1087-1090. Pubmedid: 23025947.
  • Kounalakis N, Pezner R, Staud CL, Kruper L. Partial breast irradiation in a patient with bilateral breast cancers and CREST syndrome. Brachytherapy. 2012 Feb.10(6):486-490. Pubmedid: 21349774.
  • Kruper L, Xu X, Henderson K, Bernstein L. Disparities in reconstruction rates after mastectomy for ductal carcinoma in situ (DCIS): patterns of care and factors associated with the use of breast reconstruction for DCIS compared with invasive cancer. Ann Surg Oncol. 2011 Oct.18(11):3210-3219. Pubmedid: 21863363.
  • Wiatrek R, Kruper L. Sentinel lymph node biopsy indications and controversies in breast cancer. Maturitas. 2011 May.69(1):7-10. Pubmedid: 21411254.
  • Kruper L, Holt A, Xu XX, Duan L, Henderson K, Bernstein L, Ellenhorn J. Disparities in reconstruction rates after mastectomy: patterns of care and factors associated with the use of breast reconstruction in Southern California. Ann Surg Oncol. 2011 Aug.18(8):2158-2165. Pubmedid: 21308486.
  • Pal SK, Lau SK, Kruper L, Nwoye U, Garberoglio C, Gupta RK, Paz B, Vora L, Guzman E, Artinyan A, Somlo G. Papillary carcinoma of the breast: an overview. Breast Cancer Res Treat. 2010 Aug.122(3):637-645. Pubmedid: 20524058. Pmcid: PMC3244819.
  • Kruper L, Giuliano AE. A randomized clinical trial on sentinel lymph node dissection versus axillary dissection: a matter of technique. Ann Surg. 2008 Feb.247(2):214-216. Pubmedid: 18216524.
  • Kruper L, Kurichi JE, Sonnad SS. Methodologic quality of cost-effectiveness analyses of surgical procedures. Ann Surg. 2007 Jan.245(1):147-151. Pubmedid: 17197978. Pmcid: PMC1867951.
  • Kruper LL, Spitz FR, Czerniecki BJ, Fraker DL, Blackwood-Chirchir A, Ming ME, Elder DE, Elenitsas R, Guerry D, Gimotty PA. Predicting sentinel node status in AJCC stage I/II primary cutaneous melanoma. Cancer. 2006 Nov.107(10):2436-2445. Pubmedid: 17058288.
  • Kruper LL, Low DW, Bucky LP. Immediate pectoralis flap closure following septic arthritis of the manubriosternal joint. Plast Reconstr Surg. 2001 Apr.107(4):997-999. Pubmedid: 11252094.

Patient Comments
Overall Satisfaction
4.9

10 patients rated this provider

The Provider Rating is an average of all responses to specific care provider-related questions from our nationally-recognized Press Ganey Patient Satisfaction Survey. These surveys assess the experience of our patients when visiting us for an Outpatient Clinic, Urgent Care or Virtual Health (Telemedicine) visit. Responses are measured on a scale of 1 to 5 with 5 being the best score.

Patients that are treated in outpatient or hospital environments may receive different surveys, and the volume of responses will vary by question.

Learn more about our patient satisfaction survey

Comments ()

Comments are gathered from specific care provider-related questions from our Patient Satisfaction Survey . The comments are submitted by patients and reflect their views and opinions. Patients are de-identified for confidentiality and patient privacy.

We post both positive and negative comments from the surveys. We do not post comments that are libelous, slanderous, profane, irrelevant or otherwise inappropriate or may risk the privacy of our patients. A “[…]” in the comments below indicates de-identified patient information or comments that are unrelated to the patient’s experience with the visit to the provider, such as comments related to another provider, about the survey itself, or otherwise completely off-topic.

Not all providers will have a star rating or comments. In order to ensure accuracy of our ratings, we only display ratings for providers who have a minimum of 30 completed from the previous 12 months.

Learn more about our patient comments

Provider Ratings and comments are gathered from our nationally-recognized Press Ganey Patient Satisfaction Survey. If a provider does not have ratings or comments listed it can be for several reasons, including:

  • The provider has not yet received the minimum number of patient satisfaction surveys to be eligible for display. We require a minimum of 30 surveys before we post results to ensure that the rating is statistically reliable and a true reflection of patient satisfaction.
  • He or she may be a researcher or other type of provider that does not see patients.
  • The provider practices in a specialty or office that does not use the specified surveys currently used for these ratings.
Learn more about our patient satisfaction survey, ratings and comments